Novo Nordisk blueprints new stem cell manufacturing site; Clovis bags a BTD for Rubraca
→ Just a few weeks after Clovis execs $CLVS agreed to pay more than $20 million to settle an SEC probe into the way they lied about the roci data, the company has won a breakthrough drug designation from the FDA that has investors in good humor. The BTD goes to Rubraca (rucaparib) as a monotherapy treatment of adult patients with BRCA1/2-mutated mCRPC who have received at least one prior androgen receptor-directed therapy and taxane-based chemotherapy. Its stock was up 10% in early trading Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
